Stephens & Co. analyst Jacob Johnson maintains Bio-Techne (NASDAQ:TECH) with a Overweight, adjusts price target to $105 – 4-for-1 stock split.
Tenet Healthcare Q2 Outlook: Revenue $4.9B-$5.1B Vs. $4.98B Estimate, Adj. EPS $1.58-$1.98 Vs. $1.41 Estimate, GAAP EPS $1.49-$1.93 Vs. $1.38 Estimate
2024 Outlook1
Tenet's Outlook for full year 2024 (consolidated and by segment) and second quarter 2024 follows. This outlook reflects the completion of the sale of three Coastal South Carolina hospitals on January
